Italian drugmaker Zambon is looking to China and the U.S. to grow its respiratory and nervous system portfolio and could spend more than 100 million euros ($114 million) on the right acquisition, its chief executive said.
from Reuters: Health https://reut.rs/2FYuAXi
via IFTTT
0 comments: